14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $141.16 $183.01 Monday, 6th May 2024 CANF stock ended at $2.11. This is 0.96% more than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 9.95% from a day low at $2.11 to a day high of $2.32.
90 days $141.16 $227.30
52 weeks $84.73 $227.30

Historical Can-Fite BioPharma Ltd prices

Date Open High Low Close Volume
Sep 30, 2022 $0.770 $0.790 $0.742 $0.770 40 686
Sep 29, 2022 $0.790 $0.790 $0.765 $0.770 48 571
Sep 28, 2022 $0.750 $0.790 $0.750 $0.790 38 356
Sep 27, 2022 $0.760 $0.760 $0.741 $0.753 29 028
Sep 26, 2022 $0.770 $0.780 $0.746 $0.760 46 693
Sep 23, 2022 $0.83 $0.83 $0.740 $0.744 160 734
Sep 22, 2022 $0.82 $0.86 $0.80 $0.81 34 594
Sep 21, 2022 $0.91 $0.91 $0.82 $0.84 56 565
Sep 20, 2022 $0.87 $0.87 $0.80 $0.82 52 637
Sep 19, 2022 $0.87 $0.89 $0.86 $0.87 76 040
Sep 16, 2022 $0.91 $0.92 $0.86 $0.90 47 327
Sep 15, 2022 $0.95 $0.95 $0.91 $0.91 33 990
Sep 14, 2022 $0.91 $0.94 $0.91 $0.91 24 807
Sep 13, 2022 $0.92 $0.95 $0.85 $0.91 108 042
Sep 12, 2022 $0.94 $0.97 $0.91 $0.93 77 737
Sep 09, 2022 $0.90 $0.94 $0.89 $0.93 24 214
Sep 08, 2022 $0.86 $0.89 $0.86 $0.89 32 280
Sep 07, 2022 $0.87 $0.89 $0.85 $0.89 55 228
Sep 06, 2022 $0.87 $0.90 $0.87 $0.87 23 269
Sep 02, 2022 $0.92 $0.92 $0.87 $0.87 15 858
Sep 01, 2022 $0.94 $0.94 $0.83 $0.90 63 210
Aug 31, 2022 $0.92 $0.97 $0.88 $0.94 44 057
Aug 30, 2022 $0.99 $0.99 $0.88 $0.93 102 969
Aug 29, 2022 $0.99 $1.00 $0.95 $0.97 197 874
Aug 26, 2022 $0.99 $0.99 $0.93 $0.96 80 983
Click to get the best stock tips daily for free!

About Can-Fite BioPharma Ltd

Can-Fite BioPharma Ltd Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical tria... CANF Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT